Literature DB >> 18063919

Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications.

Anna Jamroz-Wiśniewska1, Grazyna Wójcicka, Krzysztof Horoszewicz, Jerzy Bełtowski.   

Abstract

Liver X receptors (LXRs) alpha and ss belong to a group of nuclear receptors which, after ligand binding, regulate gene transcription. Their natural agonists are oxidized cholesterol derivatives (oxysterols). The main function of LX receptors is the regulation of cholesterol metabolism. In the first part of this work we discussed the structure and mechanism of action of LXRs, their agonists and antagonists, the regulation of LXR expression, and their role in cholesterol and lipid metabolism. In the present article we describe other roles of LXRs. Agonists of these receptors increase insulin sensitivity and stimulate insulin secretion. Activation of LXRs inhibits inflammation and autoimmune reactions. Moreover, pharmacological studies and genetic manipulations indicate that these receptors inhibit atherogenesis. LX receptors are also involved in the regulation of renin secretion, inhibit the formation of amyloid ss in the central nervous system, regulate gonadal function and steroidogenesis both in gonads and in adrenals, influence the proliferation and differentiation of keratinocytes, and inhibit the proliferation of tumor cells. Changes in the expression of these receptors and in the level of their agonists are observed in many diseases. Taking into account the multiple roles of LX receptors, their agonists may be applied in the future in the treatment of many disorders, including diabetes, inflammatory diseases, atherosclerosis, Alzheimer's disease, and hypogonadism. However, possible side effects should be taken into account, including enhancement of lipogenesis, hypertriglyceridemia, and liver steatosis. The function of LX receptors is also modulated by many currently used drugs such as statins, fibrates, and thazolidinedione derivatives.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063919

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  17 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Hormonal modulators of glial ABCA1 and apoE levels.

Authors:  Jianjia Fan; Yoko Shimizu; Jeniffer Chan; Anna Wilkinson; Ayaka Ito; Peter Tontonoz; Edie Dullaghan; Liisa A M Galea; Tom Pfeifer; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2013-09-02       Impact factor: 5.922

3.  Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Authors:  Colin A Flaveny; Kristine Griffett; Bahaa El-Dien M El-Gendy; Melissa Kazantzis; Monideepa Sengupta; Antonio L Amelio; Arindam Chatterjee; John Walker; Laura A Solt; Theodore M Kamenecka; Thomas P Burris
Journal:  Cancer Cell       Date:  2015-06-25       Impact factor: 31.743

4.  Cholesterol 25-hydroxylation activity of CYP3A.

Authors:  Akira Honda; Teruo Miyazaki; Tadashi Ikegami; Junichi Iwamoto; Tomomi Maeda; Takeshi Hirayama; Yoshifumi Saito; Tamio Teramoto; Yasushi Matsuzaki
Journal:  J Lipid Res       Date:  2011-05-16       Impact factor: 5.922

5.  ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.

Authors:  James J Donkin; Sophie Stukas; Veronica Hirsch-Reinshagen; Dhananjay Namjoshi; Anna Wilkinson; Sharon May; Jeniffer Chan; Jianjia Fan; Jon Collins; Cheryl L Wellington
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

Review 6.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

7.  Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Authors:  Valérie Leduc; Dorothée Domenger; Louis De Beaumont; Daphnée Lalonde; Stéphanie Bélanger-Jasmin; Judes Poirier
Journal:  Int J Alzheimers Dis       Date:  2011-04-05

8.  Dietary cholesterol-induced post-testicular infertility.

Authors:  Aurélia Ouvrier; Georges Alves; Christelle Damon-Soubeyrand; Geoffroy Marceau; Rémi Cadet; Laurent Janny; Florence Brugnon; Ayhan Kocer; Aurélien Pommier; Jean-Marc A Lobaccaro; Joël R Drevet; Fabrice Saez
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

9.  Liver X receptor α activation with the synthetic ligand T0901317 reduces lung injury and inflammation after hemorrhage and resuscitation via inhibition of the nuclear factor κB pathway.

Authors:  Patrick D Solan; Giovanna Piraino; Paul W Hake; Alvin Denenberg; Michael O'Connor; Alex Lentsch; Basilia Zingarelli
Journal:  Shock       Date:  2011-04       Impact factor: 3.454

10.  The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E.

Authors:  Dhananjay R Namjoshi; Georgina Martin; James Donkin; Anna Wilkinson; Sophie Stukas; Jianjia Fan; Michael Carr; Sepideh Tabarestani; Kelli Wuerth; Robert E W Hancock; Cheryl L Wellington
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.